Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 juil. 2026 00h10 HE | Source: Clinuvel Pharmaceuticals Limited

CLINUVEL implements strategic reorganisation to refocus on U.S. markets

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and...
20 juil. 2026 01h37 HE | Source: Clinuvel Pharmaceuticals Limited

CLINUVEL’s ADS to commence trading on Nasdaq

MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is expected to commence trading on the...
13 juil. 2026 01h10 HE | Source: Clinuvel Pharmaceuticals Limited

SCENESSE® approved for EPP in Canada

MELBOURNE, Australia, July 13, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s novel drug SCENESSE® (afamelanotide) has been granted a Notice of Compliance (NOC) by Health Canada for the prevention of...
02 juil. 2026 06h00 HE | Source: Treos Bio Corp.

Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer

LONDON and BOSTON and BUDAPEST, Hungary, July 02, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage biotechnology company developing off-the-shelf and personalized active cancer immunotherapies...
23 juin 2026 07h00 HE | Source: Oryn Therapeutics

Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers

Novel immune reprogramming oral macrocyclic peptides designed for precise modulation of complex biological networks involved in inflammatory, autoimmune and fibro-inflammatory diseases Company...
28 mai 2026 07h00 HE | Source: Treos Bio Corp.

TREOS Bio Appoints Sunjeet Sawhney as Chief Executive Officer

LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- TREOS Bio, a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, supported by biomarker-guided...
07 avr. 2026 10h06 HE | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Report, February 2026: Latest Business Conditions, New Outsourcing Contracts, Opportunity Assessment, Threats for Manufacturers, Mergers, Acquisitions, and Financing

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, February 2026" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...
27 mars 2026 11h15 HE | Source: Research and Markets

Bispecific T-Cell Engagers Market Insights Report (2026-2030) Featuring Strategic Analysis of Pfizer, Johnson & Johnson, Roche, AbbVie, Sanofi and Other Key Players

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Bispecific T-Cell Engagers Market Report 2026" has been added to ResearchAndMarkets.com's offering. The bispecific T-cell engagers market is...
18 févr. 2026 11h26 HE | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Report December 2025: Trump Administration Sets Deadline for Pharma Companies to Fulfill MFN Commitments/UK-US Tariff Deal and Pricing Reforms Position UK As Global Hub

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, December 2025" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...
26 janv. 2026 04h15 HE | Source: Research and Markets

Spine Biologic Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Spine Biologic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...

Page suivante